Articles

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

GMMG and University Hospital, Cologne, Germany
HOVON, The Netherlands
GMMG, Germany
HOVON, The Netherlands
HOVON, The Netherlands
GMMG and University Hospital and National Center for Tumor Diseases, Heidelberg, Germany
GMMG, Germany
HOVON, The Netherlands
GMMG, Germany
HOVON, The Netherlands
GMMG, Germany
GMMG, Germany
HOVON, The Netherlands
GMMG and University Hospital and National Center for Tumor Diseases, Heidelberg, Germany
Janssen Research & Development, Beerse, Belgium
GMMG, Germany
HOVON, The Netherlands
GMMG, Germany
HOVON, The Netherlands
GMMG, Germany
GMMG, Germany
HOVON, The Netherlands
GMMG, Germany
HOVON, The Netherlands
HOVON, The Netherlands
HOVON, The Netherlands
HOVON, The Netherlands
GMMG and University Hospital and National Center for Tumor Diseases, Heidelberg, Germany
HOVON, The Netherlands
Vol. 99 No. 1 (2014): January, 2014 https://doi.org/10.3324/haematol.2013.087585